Navigation Links
Alexion Acquires All Rights to OMRF Patents Related to Soliris(R)
Date:2/14/2008

CHESHIRE, Conn., Feb. 14 /PRNewswire-FirstCall/ -- The Oklahoma Medical Research Foundation ("OMRF") and Alexion Pharmaceuticals, Inc. ("Alexion," Nasdaq: ALXN) today announced that Alexion has agreed to acquire from OMRF all rights to certain patents related to complement-inhibition technology.

Background

The patents cover inventions made by OMRF in the 1980s relating to the treatment of complement system mediated disorders, to which Alexion has had limited rights as a licensee since the inception of the company. In the 1990s, Alexion began programs to create and develop monoclonal antibodies capable of blocking the body's complement system. One result of these Alexion programs was the development of Soliris(R), which was approved for marketing by the U.S. Food and Drug Administration and by the European Commission during 2007. Soliris(R) (eculizumab) is a complement inhibitor product developed and marketed by Alexion for the treatment of paroxysmal nocturnal hemoglobinuria ("PNH"), a rare, debilitating and life-threatening disease.

"Soliris opened a major new therapeutic avenue for patients with PNH, and the scientists at Alexion had to overcome tremendous obstacles to make this treatment a reality," said OMRF President Stephen Prescott, M.D. "I am proud that Peter Sims, M.D., Ph.D., and Therese Wiedmer, Ph.D., while working as scientists at OMRF and in their subsequent careers, had the opportunity to contribute to bringing this much-needed treatment to patients suffering from a life-threatening disease."

"Complex scientific breakthroughs are often built by combining research advances from different sources," said David Keiser, President and Chief Operating Officer of Alexion. "OMRF is widely respected for its technological accomplishments, and we thank the OMRF team for its contributions to the development of our anti-complement technology."

Under an agreement recently executed by the two organizations, Alexion will pay O
'/>"/>

SOURCE Alexion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Alexion Pharmaceuticals Invites You to Participate in its Fourth Quarter and Full Year 2007 Results Conference Call and Web Cast
2. Alexion to Present at Bear Stearns Healthcare Conference
3. Linc Facility Services Acquires Morse Medical
4. Acrongenomics Acquires Equity Stake in Molecular Vision
5. Inverness Medical Innovations Acquires ParadigmHealth
6. LeMaitre Vascular Acquires Biomateriali, a Vascular Graft Manufacturer
7. Thermo Fisher Scientific Acquires Leading Chromatography Consumables Provider, La-Pha-Pack
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Bayer CropSciences Vegetable Seed Business Nunhems Acquires US Lettuce Seed Company Paragon Seed
10. Neogen Acquires Assets of Rivard Instruments
11. Advanced Instruments Acquires Mart Microbiology B.V.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... May 27, 2015 Empowering biomedical ... combat disease, Cubresa Inc. today announced its MR ... Compatible in-bore PET Scanner uses silicon photomultiplier detector ... preclinical MRI machines from manufacturers like Bruker and ... in Winnipeg, Canada. “This enables simultaneous PET and ...
(Date:5/27/2015)... -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO ) ("NW Bio"), ... cancer, announced today that Dr. Marnix L. Bosch ... making an Industry Expert Theater Presentation at the 2015 ... on Saturday, May 30, 2015, from 3 to 4 ... Place. Dr. Bosch will provide an overview ...
(Date:5/27/2015)... 2015  Ceres, Inc. (Nasdaq: CERE ), an ... for a genetic sequence derived from soybean, covering uses ... development and plant transformation. The company believes that its ... are the target of a class of commercial herbicides. ... license to the innovation, including an opportunity for exclusivity ...
(Date:5/27/2015)... Mass. , May 27, 2015  RXi ... company focused on discovering and developing innovative therapies ... today provided an update on the status of the ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... were 3,085 and 21 shares of Series A ...
Breaking Biology Technology:Cubresa Launches Simultaneous PET/MRI Technology 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 2NW Bio To Present Overview Of DCVax-Direct Phase I Trial In Chicago This Weekend 3Ceres Awarded Patent for Innovation in Soybean 2Ceres Awarded Patent for Innovation in Soybean 3RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3
... In mid-March the German,Bundestag (Lower House) is due ... Act. The opposing poles in the debate on embryonic ... are calling for the complete,liberalisation of stem cell research, ... on the use of human stem cells, which are ...
... 5 Novo Nordisk, a,healthcare company with an ... today announced plans to expand its U.S. headquarters ... five years, the company,has experienced a 150 percent ... new building will have the capacity for more ...
... 5 Edwards Lifesciences,Corporation (NYSE: EW ), ... valves,today announced the first three human implants of ... John Webb, M.D.,director of the cath lab and ... Columbia., "Edwards is proud to extend our ...
Cached Biology Technology:A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 2A New Era in Cell Biology: German Company Develops Groundbreaking Alternative to Stem Cell Therapy 3Novo Nordisk Expands U.S. Headquarters in New Jersey 2Novo Nordisk Expands U.S. Headquarters in New Jersey 3Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve 2Edwards Lifesciences Announces First Human Implants of Next-Generation Transcatheter Heart Valve 3
(Date:5/5/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market, reminds investors and media that  Mr. David ... CARTES SECURE CONNEXIONS AMERICA 2015, held in Washington ... three-day conference is organized into a series of nine session ... Global Fraud: Where is the Trust in Cyberspace? and ...
(Date:4/20/2015)... Huntington Memorial Hospital is the first facility ... miniaturized, wireless monitoring sensor to manage heart failure (HF). ... FDA-approved heart failure monitoring device that has been proven ... to manage heart failure. The CardioMEMS HF ... pulmonary artery (PA) during a non-surgical procedure to directly ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
Breaking Biology News(10 mins):NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... initiating molecular mechanism in sporadic Alzheimer,s disease (AD). ... December 26th issue of the journal Neuron ... amyloid β (Aβ) plaques within the AD brain ... and disease-modifying therapies for AD, especially those aimed ...
... of Scripps Research Institute scientists, along with colleagues from ... from physics to deliver one of those research raritiesan ... that, with remarkable accuracy, predicts how bacterial proteins fold ... capability, described in this week,s Early Edition of the ...
... typically without symptoms until it has spread to other organs, ... chemotherapies show great promise for extending survival during later disease ... In one of the first discoveries of its kind, UC ... cancer gene,s own repair mechanism and, in so doing, help ...
Cached Biology News:Impaired energy metabolism linked with initiation of plaques in Alzheimer's brain 2New technique is quantum leap forward in understanding proteins 2New technique is quantum leap forward in understanding proteins 3New technique is quantum leap forward in understanding proteins 4UC Davis discovery offers hope for treating kidney cancer 2
... is a new-generation siRNA transfection reagent that ... 1 nM siRNA in a wide variety ... cell viability. Using low siRNA concentrations avoids ... when transfecting siRNA at higher concentrations, thereby ...
... and Tissue Staining Kits are intended for ... of histological and cytological specimens. These kits ... manufactured by either R&D Systems or by ... the formation of the Avidin-Biotin Complex (ABC) ...
... Cellular uptake of long double stranded RNA ... interference in a diverse group of organisms ... RNA interference leads to the inhibition of ... of the target messenger RNA (mRNA). Attempts ...
... an easy-to-use siRNA transfection reagent that has ... in a variety of cell lines. jetSI-ENDO ... optimized, straightforward protocol. High levels of gene ... transfection of 20 to 100 nM of ...
Biology Products: